# CORRESP — 20/20 Biolabs, Inc.  (AIDX)  (CIK 0001139685)

> <strong>20/20 Biolabs, Inc.  (AIDX)  (CIK 0001139685) → SEC staff</strong> · filed 2026-04-08 · ticker AIDX · SIC 8734

## What is this

A CORRESP letter is the company's written reply to the SEC during a filing review. Responses include accounting position arguments, restatement assessments, and clarifying disclosures. Released to EDGAR alongside the SEC's UPLOAD letters.

## Key facts

- **Accession number:** 0001213900-26-041468
- **Form:** CORRESP
- **Filer:** 20/20 Biolabs, Inc.  (AIDX)  (CIK 0001139685)
- **CIK:** 0001139685
- **Ticker:** AIDX
- **Filed:** 2026-04-08
- **SIC industry:** 8734
- **HQ:** Rockville, MD

## Primary source

PDF letter: https://www.sec.gov/Archives/edgar/data/1139685/000121390026041468/filename1.htm

EDGAR review history for this filer: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1139685&type=UPLOAD&dateb=&owner=include&count=40

## Other comment-letter activity for 20/20 Biolabs, Inc.  (AIDX)  (CIK 0001139685)

- UPLOAD — 2026-04-08 — /comment-letter/0000000000-26-003549

## Citation

> US Securities and Exchange Commission, EDGAR CORRESP comment letter, 20/20 Biolabs, Inc.  (AIDX)  (CIK 0001139685) (CIK 0001139685), filed 2026-04-08, accession 0001213900-26-041468. Retrieved via MORVS 2026-11-20 from https://api.morvs.ai/comment-letter/0001213900-26-041468.

---

*[SEC comment letters dataset](/datasets/sec-comment-letters) · CC0 1.0*
